Alternate fractionation for hepatic tumors

Alejandra Méndez Romero, Thomas B. Brunner, Alexander V. Kirichenko, Wolfgang A. Tome, Yun Liang, Nathan Ogden, Ben J.M. Heijmen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Historically, the liver was thought to be an organ unsuitable for radical doses needed to treat primary or secondary tumors. This determination was made in the time where only 2D treatment planning was available (Ingold et al. 1965; Wharton et al. 1973). However, the consequent interpretation of liver toxicities with 3D-conformal radiotherapy with the use of dose–volume histograms allowed us to describe the normal tissue complication probability (NTCP) characteristics of the liver, an organ with a parallel tissue structure which is reflected in a high “volume effect parameter,” n = 0.69 (Jackson et al. 1995). The data underlying the NTCP modeling came from a series of 79 patients including nine patients that developed clinical radiation hepatitis. All of the patients with radiation hepatitis, also called radiation-induced liver disease (RILD), had whole-liver radiation with doses of at least 37 Gy in conventional fractionation. On the other hand, patients who had partial liver radiotherapy to much higher doses did not develop RILD. Subsequently, a phase I trial of escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine (FUdR) was conducted for patients with unresectable intrahepatic malignancies (Dawson et al. 2000). Twenty-seven patients had hepatobiliary cancer and 16 colorectal liver metastases. This trial employed a dose per fraction of 1.5 Gy twice daily with concomitant intra-arterial FUdR during the first 4 weeks of radiotherapy. Continuous-infusion FUdR required placement of a percutaneous brachial artery catheter to deliver a dose of 0.2 mg/kg/d. The trial was designed to be isotoxic and to escalate radiation dose in cases where the target volumes were small enough to allow dose escalation according to the above-described NTCP model. This resulted in a median radiotherapy dose of 58.5 Gy with a range from 28.5 to 90 Gy. Of note, the median tumor size was as large as 10 × 10 × 8 cm. The dose to the stomach and duodenum was restricted to a maximum of 68 Gy in 1.5 Gy fractions. Twenty-five patients were assessable for response evaluation achieving 16 partial and 1 complete response. Intriguingly, improved progression-free and overall survival depended on multivariate analysis on escalated dose. There was only one incidence of late liver toxicity, namely one patient suffering a reversible grade 3 RILD.

Original languageEnglish (US)
Title of host publicationMedical Radiology
PublisherSpringer Verlag
Pages173-201
Number of pages29
DOIs
StatePublished - Jan 1 2018

Publication series

NameMedical Radiology
ISSN (Print)0942-5373
ISSN (Electronic)2197-4187

Fingerprint

Radiation
Liver
Floxuridine
Neoplasms
Liver Diseases
Radiotherapy
Hepatitis
Conformal Radiotherapy
Brachial Artery
Hepatic Artery
Duodenum
Disease-Free Survival
Colorectal Neoplasms
Stomach
Multivariate Analysis
Catheters
Neoplasm Metastasis
Incidence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Méndez Romero, A., Brunner, T. B., Kirichenko, A. V., Tome, W. A., Liang, Y., Ogden, N., & Heijmen, B. J. M. (2018). Alternate fractionation for hepatic tumors. In Medical Radiology (pp. 173-201). (Medical Radiology). Springer Verlag. https://doi.org/10.1007/174_2017_35

Alternate fractionation for hepatic tumors. / Méndez Romero, Alejandra; Brunner, Thomas B.; Kirichenko, Alexander V.; Tome, Wolfgang A.; Liang, Yun; Ogden, Nathan; Heijmen, Ben J.M.

Medical Radiology. Springer Verlag, 2018. p. 173-201 (Medical Radiology).

Research output: Chapter in Book/Report/Conference proceedingChapter

Méndez Romero, A, Brunner, TB, Kirichenko, AV, Tome, WA, Liang, Y, Ogden, N & Heijmen, BJM 2018, Alternate fractionation for hepatic tumors. in Medical Radiology. Medical Radiology, Springer Verlag, pp. 173-201. https://doi.org/10.1007/174_2017_35
Méndez Romero A, Brunner TB, Kirichenko AV, Tome WA, Liang Y, Ogden N et al. Alternate fractionation for hepatic tumors. In Medical Radiology. Springer Verlag. 2018. p. 173-201. (Medical Radiology). https://doi.org/10.1007/174_2017_35
Méndez Romero, Alejandra ; Brunner, Thomas B. ; Kirichenko, Alexander V. ; Tome, Wolfgang A. ; Liang, Yun ; Ogden, Nathan ; Heijmen, Ben J.M. / Alternate fractionation for hepatic tumors. Medical Radiology. Springer Verlag, 2018. pp. 173-201 (Medical Radiology).
@inbook{ac2f5173072d46baad780b90fb7ced19,
title = "Alternate fractionation for hepatic tumors",
abstract = "Historically, the liver was thought to be an organ unsuitable for radical doses needed to treat primary or secondary tumors. This determination was made in the time where only 2D treatment planning was available (Ingold et al. 1965; Wharton et al. 1973). However, the consequent interpretation of liver toxicities with 3D-conformal radiotherapy with the use of dose–volume histograms allowed us to describe the normal tissue complication probability (NTCP) characteristics of the liver, an organ with a parallel tissue structure which is reflected in a high “volume effect parameter,” n = 0.69 (Jackson et al. 1995). The data underlying the NTCP modeling came from a series of 79 patients including nine patients that developed clinical radiation hepatitis. All of the patients with radiation hepatitis, also called radiation-induced liver disease (RILD), had whole-liver radiation with doses of at least 37 Gy in conventional fractionation. On the other hand, patients who had partial liver radiotherapy to much higher doses did not develop RILD. Subsequently, a phase I trial of escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine (FUdR) was conducted for patients with unresectable intrahepatic malignancies (Dawson et al. 2000). Twenty-seven patients had hepatobiliary cancer and 16 colorectal liver metastases. This trial employed a dose per fraction of 1.5 Gy twice daily with concomitant intra-arterial FUdR during the first 4 weeks of radiotherapy. Continuous-infusion FUdR required placement of a percutaneous brachial artery catheter to deliver a dose of 0.2 mg/kg/d. The trial was designed to be isotoxic and to escalate radiation dose in cases where the target volumes were small enough to allow dose escalation according to the above-described NTCP model. This resulted in a median radiotherapy dose of 58.5 Gy with a range from 28.5 to 90 Gy. Of note, the median tumor size was as large as 10 × 10 × 8 cm. The dose to the stomach and duodenum was restricted to a maximum of 68 Gy in 1.5 Gy fractions. Twenty-five patients were assessable for response evaluation achieving 16 partial and 1 complete response. Intriguingly, improved progression-free and overall survival depended on multivariate analysis on escalated dose. There was only one incidence of late liver toxicity, namely one patient suffering a reversible grade 3 RILD.",
author = "{M{\'e}ndez Romero}, Alejandra and Brunner, {Thomas B.} and Kirichenko, {Alexander V.} and Tome, {Wolfgang A.} and Yun Liang and Nathan Ogden and Heijmen, {Ben J.M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/174_2017_35",
language = "English (US)",
series = "Medical Radiology",
publisher = "Springer Verlag",
pages = "173--201",
booktitle = "Medical Radiology",

}

TY - CHAP

T1 - Alternate fractionation for hepatic tumors

AU - Méndez Romero, Alejandra

AU - Brunner, Thomas B.

AU - Kirichenko, Alexander V.

AU - Tome, Wolfgang A.

AU - Liang, Yun

AU - Ogden, Nathan

AU - Heijmen, Ben J.M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Historically, the liver was thought to be an organ unsuitable for radical doses needed to treat primary or secondary tumors. This determination was made in the time where only 2D treatment planning was available (Ingold et al. 1965; Wharton et al. 1973). However, the consequent interpretation of liver toxicities with 3D-conformal radiotherapy with the use of dose–volume histograms allowed us to describe the normal tissue complication probability (NTCP) characteristics of the liver, an organ with a parallel tissue structure which is reflected in a high “volume effect parameter,” n = 0.69 (Jackson et al. 1995). The data underlying the NTCP modeling came from a series of 79 patients including nine patients that developed clinical radiation hepatitis. All of the patients with radiation hepatitis, also called radiation-induced liver disease (RILD), had whole-liver radiation with doses of at least 37 Gy in conventional fractionation. On the other hand, patients who had partial liver radiotherapy to much higher doses did not develop RILD. Subsequently, a phase I trial of escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine (FUdR) was conducted for patients with unresectable intrahepatic malignancies (Dawson et al. 2000). Twenty-seven patients had hepatobiliary cancer and 16 colorectal liver metastases. This trial employed a dose per fraction of 1.5 Gy twice daily with concomitant intra-arterial FUdR during the first 4 weeks of radiotherapy. Continuous-infusion FUdR required placement of a percutaneous brachial artery catheter to deliver a dose of 0.2 mg/kg/d. The trial was designed to be isotoxic and to escalate radiation dose in cases where the target volumes were small enough to allow dose escalation according to the above-described NTCP model. This resulted in a median radiotherapy dose of 58.5 Gy with a range from 28.5 to 90 Gy. Of note, the median tumor size was as large as 10 × 10 × 8 cm. The dose to the stomach and duodenum was restricted to a maximum of 68 Gy in 1.5 Gy fractions. Twenty-five patients were assessable for response evaluation achieving 16 partial and 1 complete response. Intriguingly, improved progression-free and overall survival depended on multivariate analysis on escalated dose. There was only one incidence of late liver toxicity, namely one patient suffering a reversible grade 3 RILD.

AB - Historically, the liver was thought to be an organ unsuitable for radical doses needed to treat primary or secondary tumors. This determination was made in the time where only 2D treatment planning was available (Ingold et al. 1965; Wharton et al. 1973). However, the consequent interpretation of liver toxicities with 3D-conformal radiotherapy with the use of dose–volume histograms allowed us to describe the normal tissue complication probability (NTCP) characteristics of the liver, an organ with a parallel tissue structure which is reflected in a high “volume effect parameter,” n = 0.69 (Jackson et al. 1995). The data underlying the NTCP modeling came from a series of 79 patients including nine patients that developed clinical radiation hepatitis. All of the patients with radiation hepatitis, also called radiation-induced liver disease (RILD), had whole-liver radiation with doses of at least 37 Gy in conventional fractionation. On the other hand, patients who had partial liver radiotherapy to much higher doses did not develop RILD. Subsequently, a phase I trial of escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine (FUdR) was conducted for patients with unresectable intrahepatic malignancies (Dawson et al. 2000). Twenty-seven patients had hepatobiliary cancer and 16 colorectal liver metastases. This trial employed a dose per fraction of 1.5 Gy twice daily with concomitant intra-arterial FUdR during the first 4 weeks of radiotherapy. Continuous-infusion FUdR required placement of a percutaneous brachial artery catheter to deliver a dose of 0.2 mg/kg/d. The trial was designed to be isotoxic and to escalate radiation dose in cases where the target volumes were small enough to allow dose escalation according to the above-described NTCP model. This resulted in a median radiotherapy dose of 58.5 Gy with a range from 28.5 to 90 Gy. Of note, the median tumor size was as large as 10 × 10 × 8 cm. The dose to the stomach and duodenum was restricted to a maximum of 68 Gy in 1.5 Gy fractions. Twenty-five patients were assessable for response evaluation achieving 16 partial and 1 complete response. Intriguingly, improved progression-free and overall survival depended on multivariate analysis on escalated dose. There was only one incidence of late liver toxicity, namely one patient suffering a reversible grade 3 RILD.

UR - http://www.scopus.com/inward/record.url?scp=85054302106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054302106&partnerID=8YFLogxK

U2 - 10.1007/174_2017_35

DO - 10.1007/174_2017_35

M3 - Chapter

T3 - Medical Radiology

SP - 173

EP - 201

BT - Medical Radiology

PB - Springer Verlag

ER -